Ge Wei, Yu De-Cai, Li Qing-Guo, Chen Xi, Zhang Chen-Yu, Ding Yi-Tao
Clin Lab. 2014;60(3):427-34. doi: 10.7754/clin.lab.2013.130133.
Recent studies showed that serum microRNAs were aberrantly expressed in cancers, including hepatocellular carcinoma (HCC). Serum microRNA (miRNA) profiles in HCC have been filtered in our previous studies. In this research, some serum miRNAs were further validated and their clinical significances were analyzed.
Sera from 90 HCC patients, the subjects, and 60 non-HCC normal, the controls, were used. The expression of serum microRNAs was measured using real-time reverse transcription-polymerase chain reaction. AFP, as well as other clinical materials, were summarized from the HCC databases in our hospital.
Serum miR-16, let-7f, and miR-21 are down-regulated in HCC while miR-98 and miR-221 are not regulated significantly. Moreover, these miRNAs are of specific clinical significance. The expression of serum miR-16 is down-regulated in the patients with a tumor more than 5 cm in diameter (p = 0.0013) and is correlated with some quantitative clinical features such as platelets (p = 0.0255), PT (p = 0.0007) and bilirubin (p = 0.0025). The expression of serum let-7f is up-regulated in the patients with a tumor more than 5 cm in diameter (p = 0.0367) and early recurrence (p = 0.0047). The expression of serum miR-21 is up-regulated in female patients with HCC (p = 0.0297).
Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC.
近期研究表明,血清微小RNA在包括肝细胞癌(HCC)在内的多种癌症中表达异常。在我们之前的研究中已筛选了HCC患者的血清微小RNA(miRNA)谱。本研究进一步验证了部分血清miRNA,并分析了其临床意义。
使用90例HCC患者(研究对象)和60例非HCC正常者(对照)的血清。采用实时逆转录-聚合酶链反应检测血清微小RNA的表达。从我院HCC数据库中汇总甲胎蛋白(AFP)及其他临床资料。
血清miR-16、let-7f和miR-21在HCC中表达下调,而miR-98和miR-221无明显变化。此外,这些miRNA具有特定的临床意义。血清miR-16在直径大于5 cm的肿瘤患者中表达下调(p = 0.0013),且与血小板(p = 0.0255)、凝血酶原时间(PT,p = 0.0007)和胆红素(p = 0.0025)等一些定量临床特征相关。血清let-7f在直径大于5 cm的肿瘤患者(p = 0.0367)和早期复发患者(p = 0.0047)中表达上调。血清miR-21在女性HCC患者中表达上调(p = 0.0297)。
血清miR-16、let-7f和miR-21与HCC的生物学行为相关,这意味着它们可被视为评估HCC肿瘤大小或复发情况的潜在指标。